Skip to main content
. 2020 Feb 23;56(2):90. doi: 10.3390/medicina56020090

Figure 4.

Figure 4

Effect of combinatorial treatment on the proliferation of prostate cancer cells. (A) LNCaP cells treated with enzalutamide and SPME, (B) LNCaP cells treated with enzalutamide and SEME, (C) PC-3 cells treated with enzalutamide and SPME, and (D) PC-3 cells treated with enzalutamide and SEME. Cells were treated with 40 μM enzalutamide + 500 μg/mL SPME or SEME, and 40 μM of enzalutamide + 1000 μg/mL of SPME or SEME for 48 h. Values are expressed as mean ± S.E.M. Values with different letters (a–c) are significantly different (P < 0.05). Experiments were performed three times.